[Retracted] Analysis of Efficacy, Safety, and Prognostic Factors of mFOLFOX6 Regimen Combined with Cetuximab and Simvastatin in the Treatment of K-RAS Mutant Colorectal Cancer

Table 4

Univariate analysis of mean prognosis survival time in CRC patients.

Factors	Examples	The mean survival time (month)	t
Age (years)
<50	47	30.15 (25.37, 33.48)	1.572	0.119
≥50	69	28.37 (24.06, 32.22)
Sexuality
Male	64	29.45 (24.82, 33.06)	0.559	0.577
Female	52	30.08 (25.35, 33.53)
Tumor location
Left hemicolon	82	30.26 (26.57, 33.83)	1.040	0.301
Right hemicolon	34	28.97 (24.83, 32.40)
Pathological grade
Medium-high differentiation	80	34.75 (31.81, 37.56)	13.363	≤0.01
Poor differentiation	36	22.64 (19.10, 25.36)
Peritoneal metastasis
No	104	33.58 (30.42, 36.39)	7.680	≤0.01
Yes	12	23.14 (19.19, 25.42)
Chemotherapy regimen
mFOLFOX6 + cetuximab	58	26.77 (22.72, 30.15)	12.607	≤0.01
mFOLFOX6 + cetuximab + simvastatin	58	39.04 (39.04, 43.11)